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Abstract
Background: The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal
castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and
enzalutamide, target the androgen binding site of the receptor, competing with endogenous androgenic steroids. Several
AR mutations in this binding site have been associated with poor prognosis and resistance to conventional prostate
cancer drugs. In order to develop an effective CRPC therapy, it is crucial to understand the effects of these mutations on
the functionality of the AR and its ability to interact with endogenous steroids and conventional AR inhibitors.
Results: We previously utilized circulating cell-free DNA (cfDNA) sequencing technology to examine the AR gene for
the presence of mutations in CRPC patients. By modifying our sequencing and data analysis approaches, we identify
four additional single AR mutations and five mutation combinations associated with CRPC. Importantly, we conduct
experimental functionalization of all the AR mutations identified by the current and previous cfDNA sequencing to
reveal novel gain-of-function scenarios. Finally, we evaluate the effect of a novel class of AR inhibitors targeting the
binding function 3 (BF3) site on the activity of CRPC-associated AR mutants.
Conclusions: This work demonstrates the feasibility of a prognostic and/or diagnostic platform combining the direct
identification of AR mutants from patients’ serum, and the functional characterization of these mutants in order to
provide personalized recommendations regarding the best future therapy.
Keywords: Androgen receptor, Castration-resistant prostate cancer, Cell-free circulating DNA, Mutations, Drug
resistance, Anti-androgens and steroids
Background
Advances in prostate cancer (PCa) research have led to
the development of novel therapies for the metastatic
castration-resistance (CRPC) form of the disease, such
as two recent drugs abiraterone [1, 2] and enzalutamide
[3, 4], which target the androgen receptor (AR) pathway.
Abiraterone inhibits cytochrome P450 17A1 (CYP17A1),
an enzyme responsible for the synthesis of testosterone
that, after conversion to dihydrotestosterone (DHT),
binds to the androgen binding site (ABS) of the AR and
activates the AR signaling axis. Enzalutamide is a potent
anti-androgen that competes with DHT and binds to the
ABS, preventing AR transcriptional activation. Unfortu-
nately, patients with advanced PCa either do not re-
spond to anti-androgen therapy due to pre-existing
aberrations of CYP17, or AR or relapse to CRPC due to
adaptive responses, or Darwinian selection of rare
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aberrations. Thus, while these therapies improve disease
management and extend life for most patients, ultim-
ately they are only palliative.
In the majority of cases, CRPC is accompanied by re-
activation of the AR signaling axis so that the receptor
regulates its numerous target genes including PSA. Not
surprisingly, an impressive repertoire of mechanisms has
been identified that reactivate the AR signaling axis.
These include upregulation of CYP17 [5], amplification
of the AR gene [6], expression of constitutive AR splice
variants [7, 8], or mutation of the AR itself [9–12]. It has
been demonstrated that mutations in the ABS of the AR
can lead to its activation by weak adrenal androgens,
steroidal and non-steroidal ligands, and by mutation-
driven conversion of AR inhibitors into agonists [13].
For example, the AR substitution T878A, identified in
the LNCaP cell line, confers resistance to the anti-
androgen hydroxyflutamide [14] and is promiscuously
activated by progesterone and 17β-estradiol [15]. Other
mutations such as W742C/L and F877L are associated
with resistance to the anti-androgens bicalutamide
[16–18] and enzalutamide [19–21], respectively. Thus,
identification and characterization of resistance-associated
AR mutations, as biomarkers for primary treatment of
both naïve PCa and CRPC patients, are critically im-
portant for predicting, as well as monitoring, patient’s
response to therapy. This process is essential for the de-
velopment of evidence-based precision oncology.
The detection of circulating cell-free DNA (cfDNA)
has recently emerged as a non-invasive diagnostic tool
for a variety of cancers, including CRPC, and as a tech-
nology maximizing the efficacy of anticancer therapies
[22, 23]. It is estimated that up to 3 % of tumor DNA is
released into the circulatory system daily from the pro-
cesses such as secretion, necrosis, and primarily apop-
tosis [24]. In our previous work [25], we reported the
development of a sequencing platform that allowed de-
tection of a repertoire of AR mutations in cfDNA
isolated from CRPC patients. This method enabled ef-
fective sequencing of AR exon 8 from plasma samples of
47/62 metastatic CRPC patients who were progressing
on systemic therapy, and thus resulted in the identifica-
tion of numerous AR mutations, including three previ-
ously unreported ones.
By improving the sequencing and data analysis pro-
cesses, we were able to sequence the cfDNA of the 15
CRPC patients that were previously excluded due to low
yield of DNA in their plasma samples, to validate all of
the mutations reported in our previous work [25] and to
identify new candidate mutations.
Importantly, in the current work, we have also carried
out in vitro characterization of all AR mutations identi-
fied in 62 CRPC patients together with seven AR
mutants previously reported in the literature (L702H,
W742L, W742C, V716M, V731M, T878S, and M896T),
to ascertain the exact mechanisms of resistance to AR
pathway inhibitors (Fig. 1). To accomplish this task, we
engineered each one of 24 distinct AR mutants (con-
taining single and multiple amino-acid substitutions),
and determined in vitro effects of four current AR antago-
nists (enzalutamide, hydroxyflutamide, bicalutamide, and
ARN509) on all mutants, as well as investigated their in
vitro responses to four different steroids including DHT,
progesterone, estradiol, and hydrocortisone. As the result,
we present evidence that all identified AR mutations pro-
vide evolutionary escape routes from androgen blockade,
thus highlighting the need for novel AR inhibitors that
bind to the AR outside of the ABS. Finally, we demon-
strate that VPC-13566, one of our recently developed class
of AR inhibitors bearing a quinolone scaffold [26] that dir-
ectly interferes with AR recruitment of co-chaperones and
activating cofactors via binding to the BF3 surface [27,
28], effectively inactivates the AR signaling axis for all 24
CRPC-associated AR mutants.
Results
Deep sequencing reveals AR mutations in cfDNA
In the current study, we used data from a patient co-
hort we previously reported [25]. We showed that
mutations in the AR ABS contributed to treatment re-
sistance in a subset of patients and presented the possi-
bility of detecting these mutations in cfDNA at the
point of progression [25]. Due to low DNA yield
(<30 ng), 15 patients were not amenable to sequencing.
In order to overcome this limitation, we have WGA2-
amplified and sequenced cfDNA from these patients
and modified the pipeline we developed previously [25]
to enable detection of mutations in WGA2 cfDNA (see
the ‘Methods’ section for more details). We have also
performed experimental validation of the redesigned
pipeline using direct comparison of WGA2 and non-
amplified data for subset of cfDNA samples as well as
alternative sequencing platforms (see Additional file 1:
Supplementary data, Table S1).
In total, mutations were detected at 13 nucleotide po-
sitions in the coding region of exon 8 in 14/62 (23 %) of
patients (Table 1). The frequency of these mutations in
patients’ cfDNA ranged from 0.11 % to 23 %. Mutations
at two positions were silent, while mutations in the
remaining 11 resulted in 12 distinct amino-acid substitu-
tions (no nonsense mutations were detected). Two mis-
sense mutations were detected in multiple patients:
H875Y (n = 7) and T878A (n = 4). By including the
WGA2 sequencing, we were able to report four new
mutations (H875Q, D891H, E898G, and T919S) that
were neither identified in our previous study [25] nor
described in the literature.
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We previously discussed the validation of sequencing
results using MiSeq resequencing of AR exon 8 ampli-
cons and additional DNA samples from VC-012 and
VC-041 patients. Inclusion of WGA2 sequencing data
allowed us to extend the validation. For example, we
have identified M896V and S889G mutations in the
WGA2 sequence of the patient VC-012 at the first time-
point; both mutants were supported by the unamplified
sequence data from the first and/or the second time-
points. We reported that for VC-012, four additional
mutations were identified at the second (post-enzaluta-
mide) time-point, including F877L/T878A and T878A/
S889G (Fig. 2).
The cfDNA sample from the first time-point of VC-001
patient was collected at progression on abiraterone prior
to commencing enzalutamide, but the patient’s mutation
status was not reported due to low cfDNA yield. The sec-
ond sample was collected approximately 3.5 months later
at the point of progression on Enzalutamide. After WGA2
sequencing, two single (H875Y and T878A) and one
combined (H875Y/T878A) mutation were detected at
the first time-point, in addition to a silent mutation
L874L (Table 1). Two additional substitutions, D891H
and T878A/D891H, were detected at enzalutamide pro-
gression. Similar to patient VC-012, we detected mul-
tiple AR haplotypes at both time-points for VC-001,
none of which contained more than two missense
mutations.
AR transcriptional activation by steroids
The response of AR mutants to increasing concentra-
tions of DHT has been measured using a luciferase-
reporter transcription assay in PC3 cells transiently
transfected with either wild-type or mutated AR. The ex-
pression level of all of the mutants was evaluated by
western blotting (Additional file 2: Figure S1). Only two
point mutations, T878S (EC50 = 0.019 nM) and T919S
(EC50 = 0.030 nM), made the receptor slightly more
Fig. 1 AR mutations identified in CRPC patients. a AR gene organization showing the AR-LBD mutants. b AR mutants mapped on the X-ray structure
(PDB: 2 AM9) of the LBD (cartoon representation, in gray) in complex with testosterone (TES, ball-and-stick representation, in cyan). AR mutants encoded
by exon 8 are shown in magenta ball-and-stick representation. The rest of the mutants are shown in blue
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sensitive to DHT compared to the wild type (EC50 = 0.047
nM) (Table 2). Some mutants such as H875Q/T919S and
W742L/C appeared to be over-stimulated by higher con-
centrations of DHT (Fig. 3a). A noteworthy mutant was
W742L that showed an approximately two-fold higher
level of transcriptional activity than the wild-type AR at
high concentrations of DHT (approximately 500 nM)
(Table 2, Fig. 3a).
Taken together, these data illustrate the heterogeneous
responses of AR mutants towards activation by DHT;
ranging from mutation-driven enhancement of AR lig-
and sensitivity, to creation of ‘super-active’ variants of
the receptor. It is noteworthy that these CRPC mutants
may also present higher affinities toward other steroids
in order to overcome the effect of androgen deprivation
[29–31]. Therefore, we tested the response of wild-type
and mutated AR to activation by three other steroids: es-
tradiol, progesterone, and hydrocortisone. The wild-type
AR was only mildly stimulated by progesterone concen-
trations higher than 100 nM and was not activated with
estradiol or hydrocortisone at concentrations as high as
500 nM (Additional file 3: Figure S2). Regarding activa-
tion with estradiol, many mutants demonstrated a stron-
ger response to this steroid compared to the wild-type
receptor (Fig. 3b). It has been reported that H875Y,
T878A, and T878S could be activated by estrogens
Table 1 AR mutations detected in CRPC patients
Patient Amino acid change Mutant read count Wild-type read count Total read count Percent mutant
VC-001-t1* T878A 39 13,231 13,270 0.29
H875Y 36 13,351 13,387 0.27
H875Y/T878A 251 13,019 13,270 1.89
VC-001-t2 T878A 30 12,626 12,656 0.24
H875Y 0 13,307 13,307 0.00
H875Y/T878A 230 12,426 12,656 1.82
T878A/D891H 158 10,383 10,541 1.50
D891H 8 10,533 10,541 0.08
VC-005 E894K 170 10,745 10,915 1.56
VC-012-t1 M896V 1,270 5,985 7,255 17.51
VC-012-t1* S889G 307 4,769 5,076 6.05
M896V 273 5,838 6,111 4.47
VC-012-t2 S889G 103 8,202 8,305 1.24
M896V 31 8,934 8,965 0.35
H875Y 49 10,355 10,404 0.47
T878A 300 9,760 10,060 2.98
F877L/T878A 141 9,919 10,060 1.40
T878A/S889G 35 8,270 8,305 0.42
VC-014* E898G 237 11,919 12,156 1.95
VC-015 T878A 218 9,502 9,720 2.24
VC-017 T878A 99 12,626 12,725 0.78
VC-018* H875Y 223 10,382 10,605 2.10
VC-021* H875Q 251 9,846 10,097 2.49
T919S 238 9,004 9,242 2.58
VC-022 D880E 12 10,902 10,914 0.11
VC-040 H875Y 479 7,560 8,039 5.96
VC-041-t1 H875Y 1,521 7,260 8,781 17.32
VC-041-t2 H875Y 4,665 15,662 20,327 22.95
VC-053 H875Y 136 9,064 9,200 1.48
VC-063 H875Y 270 14,874 15,144 1.78
VC-064 L882I 17 15,670 15,687 0.11
Newly reported samples sequenced from WGA2 DNA are marked with a *. Each horizontal line in the table represents a particular haplotype, hence multiple lines
for some data points. Only patients with mutations detected in cfDNA or in WGA2 cfDNA are shown
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(reviewed in [13] and validated in our assay). In the
current work, we show that some of the newly reported
mutants such as D891H, T878A/D891H, and T878A/
S889G were stimulated up to eight-fold higher than the
wild-type receptor in the presence of 500 nM estradiol
(Fig. 3b, Table 2).
Nine AR mutants could be effectively stimulated by
much lower concentrations of progesterone compared
with the wild-type AR (EC50 = 104 nM). For example,
mutant T878S revealed an EC50 value of 0.53 nM (pro-
gesterone), which is 200 times higher affinity than the
wild-type AR. Similarly, mutants T878A/S889G, T878A,
T878A/D891H, F877L/T878A, H875Y, H875Y/T878A,
S889G, and D891H exhibited EC50 in the range of
nanomolar progesterone concentrations (Fig. 3c, Table 2).
Some of these mutants were previously reported to be
activated by progesterone (such as T878A/S and H875Y)
[9, 13, 31, 32].
The wild-type AR (and most of the mutants) did not
exhibit any significant transcriptional activation with
hydrocortisone at a concentration up to 500 nM, with
the exception of the L702H mutant (EC50 = 25 nM)
known to be activated by hydrocortisone [15] and
H875Y/T878A (EC50 = 105 nM) (Fig. 3d, Table 2).
AR transcriptional inhibition by AR antagonists
We have tested four current non-steroidal AR antago-
nists: hydroxyflutamide [14], bicalutamide [16, 17], enza-
lutamide [33–35], and ARN509 [36] (Table 3, Additional
file 4: Table S2) for their effects on the transcriptional
Fig. 2 Characterization of AR mutants identified in patient VC-012 after progression on bicalutamide and enzalutamide. a Two AR mutants were
identified in the cfDNA isolated after patient progression on bicalutamide. Both mutants show agonist response to bicalutamide in an in vitro
transcription assay. b Four additional mutants were identified in the same patient VC-012 after progression on enzalutamide, all with various agonist
effects toward enzalutamide in vitro. The percentage in the charts only reflects the mutated form of the androgen receptor. Each concentration was
assayed in quadruplicate n = 4, with a biological replicate of n = 3. Results were averaged and normalized by expressing them as a percentage of the
wild-type AR activity ± SEM
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activity of 24 AR mutants. Using the same luciferase
transcription assay described above, cells were stimu-
lated with the non-metabolizable androgen R1881 and
then treated with the increasing concentrations of the
drugs. This experiment allowed us to identify specific
AR mutations that decrease the sensitivity of the recep-
tor to inhibition by these antagonists as well as the
characterization of the mutations that transform current
anti-androgens into AR agonists. Thus, in addition to
the already well-documented F877L mutation that con-
verts enzalutamide to a partial agonist, we showed that
the compound mutation (F877L/T878A), that is also
present in the enzalutamide resistant cell line MR49F
[37], converted this drug into a full agonist. We have
also observed that canonical hydroxyflutamide-resistant
T878A and H875Y AR variants also confer a partial
agonist effect to enzalutamide when the drug was ad-
ministered at higher concentrations (Table 3, Fig. 2).
When T878A is combined with other LBD mutations,
such as T878A/D891H or T878A/S889G, the activation
effect of enzalutamide on the mutant is retained, and
seemingly enhanced. Of note, in the panel of 24 studied
AR variants, the experimental drug ARN509 behaved
very similarly to enzalutamide (Table 3 and Additional
file 4: Table S2), which was not surprising, considering
that a very high degree of structural resemblance exists
between the two chemicals. Moreover, our results indi-
cate that two mutants - H875Y and F877L - appear to
be more resistant to ARN509 than to enzalutamide
(Additional file 4: Table S2).
In accordance with a previous study [20], we found
that the well-documented enzalutamide- and ARN509-
resistant mutant, F877L, can effectively respond to the
older anti-androgens, bicalutamide and hydroxyfluta-
mide (Fig. 4, Additional file 4: Table S2). A similar ob-
servation was also made for the double mutant F877L/
T878A that provides a profound agonist function to
hydroxyflutamide, enzalutamide, and ARN509, but can
Table 2 The inhibition of AR mutants by VPC-13566 and their activation by various steroids










WT 1.73 0.05 >500 104.0 >500
L702H 6.13 8.00 >500 172.0 25.0
V716M 1.06 0.14 >500 329 .0 >500
V731M 0.99 0.09 >500 115.0 >500
W742L 2.29 33.60 >500 >500 >500
W742C 3.43 4.74 >500 293.0 >500
H875Y 1.34 0.14 68.0 10.20 >500
H875Q 0.79 0.43 >500 >500 >500
F877L 0.37 0.08 >500 >500 >500
T878A 2.56 0.06 144.0 0.57 >500
T878S 0.43 0.02 100.0 0.53 >500
D880E 1.14 0.11 >500 177.0 >500
L882I 0.84 0.20 >500 >500 >500
S889G 10.48 0.37 230.0 17.20 >500
D891H 2.35 0.12 173.0 31.0 >500
E894K 1.20 0.25 >500 143.0 >500
M896V 0.59 4.50 >500 >500 >500
M896T 0.10 >500 >500 >500 >500
E898G 1.24 0.45 >500 >500 >500
T919S 1.29 0.03 >500 123.0 >500
H875Q/T919S 0.63 0.18 >500 >500 >500
T878A/S889G 13.20 0.12 94.0 0.36 >500
T878A/D891H 13.40 0.40 100.0 0.49 >500
H875Y/T878A 10.80 1.26 63.0 0.66 105.0
F877L/ T878A 11.70 0.81 >500 5.70 >500
The IC50 values of the inhibition by VPC-13566 and the EC50 values of the activation by DHT, estradiol, progesterone, and hydrocortisone are reported for the
wild-type AR and the 24 studied mutants. For steroid activation, we tested a concentration range up to 500 nM, therefore mutants showing no activation or very
weak activation in the studied range are presented with EC50 values >500 nM
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be effectively suppressed by bicalutamide (Table 3,
Additional file 4: Table S2). These important cases illus-
trate that the use of cfDNA sequencing technology
could revive older treatment options for some CRPC
patients that have developed resistance to enzaluta-
mide. These results once again emphasize the import-
ance of an evidence-based approach to precision
oncology for prostate cancer patients.
We recently reported that H875Y and T878A AR mu-
tations were identified in patients progressing on abira-
terone or had previously received it [25]. Romanel et al.
also showed the emergence of T878A and L702H mu-
tants in 13 % of patients progressing on abiraterone [38].
As none of the tested mutants were activated with abira-
terone in our assay (Additional file 4: Table S2), the se-
lection for these mutants after abiraterone treatment
seems important for the AR promiscuous activation by
other steroids, especially progesterone. This suggestion
could be supported by the increase in progesterone
levels after abiraterone therapy [39].
Inhibition of AR mutants via BF3 site
One promising strategy for combating mutation-driven
drug resistance could be to develop drugs that act on
the AR outside of the ABS region. This paradigm is ex-
emplified by the recently described Binding Function-3
(BF3) - a protein-protein interaction site that is essen-
tial for AR transcriptional activity and is involved in
recruiting AR co-regulators such as FKBP52 and Bag-
1 L [27, 40]. Previously, we reported on the develop-
ment of quinolone derivatives that selectively inhibit
the AR through its BF3 functionality at clinically relevant
concentrations [26, 41–44]. One such AR inhibitor - 2-(7-
methyl-1H-indol-3-yl) quinolone (called VPC-13566),
demonstrated an IC50 of 1.73 μM in PC3 cells transfected
with WT-AR plasmid (Fig. 5a). Importantly, using a TR-
FRET assay, we showed that VPC-13566 was able to dis-
place a FITC labeled BAG1L peptide (residues 1-20) from
the BF3 pocket of AR, proving its binding to the suggested
site. However, the compound VPC-14449 [45], which tar-
gets the DNA binding domain of AR, was not able to dis-
place BAG1L from its pocket (Fig. 5b). In the current
study, we have employed the described luciferase-based
assay to assess the transcriptional activity of 24 AR mu-
tants in response to varying concentrations of VPC-
13566 (Table 2, Additional file 4: Table S2). Under the
same conditions, using an MTS cell proliferation assay,
we assessed the toxicity of this compound in non-
Fig. 3 Steroid activation of AR mutants in comparison with the wild-type receptor in luciferase reporter assay. While most of the AR mutants
showed similar or lower affinity to the activation by DHT (a), when compared to wild-type, several variants presented better activation by estradiol (b),
progesterone (c), or hydrocortisone (d) than the wild-type. PC3 cells were transfected with both wild-type or mutated AR and a reporter plasmid
pARR3-tk-luciferase. After 48 h post transfection, cells were treated with increasing concentrations of steroids. The graphs represent the average ± SEM
of three independent experiments with four replicates each. The activity of each mutant in the presence of a steroid was normalized to the wild-type
stimulated by 500 nM of the same steroid
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transfected PC3 cells and only noticed a mild toxicity
at 50 μM (Fig. 5c). We hypothesized that the AR BF3
inhibitor should not be activated by any of the muta-
tions, because they mainly cluster in the AR ABS, a re-
gion spatially distant from the BF3 site, and therefore,
should not affect the interaction of VPC-13566 with
the protein. Indeed, VPC-13566 effectively suppressed
the transcriptional activity of all 24 AR mutants with
the corresponding IC50 values in the range of 0.12 to
13.4 μM (Table 2, Additional file 4: Table S2).
Discussion
Repertoire and functionality of AR mutations
The AR is a multi-domain, ligand-inducible transcription
factor composed of an N-terminal part, followed by a
DNA binding (DBD) domain – the functional site of the
receptor, a hinge region, and finally, a C-terminal LBD
portion that is encoded by exons 5-8 and is known to be
prone to mutations (Fig. 1) [46]. The incidence of AR
mutations is rare in untreated prostate cancer, and is es-
timated to be in the range of 15 % in CRPC patients
[47]. It has been reported that certain AR mutations can
cause treatment failure of conventional AR antagonists,
and can promote progression of PCa to its lethal CRPC
state [13, 48, 49]. The accumulating evidence suggests
that temporal monitoring of PCa patients being treated
with AR pathway inhibitors can help detect the emer-
gence of resistant AR mutants that drive CRPC.
Several of these CRPC-associated mutations are well
documented in the literature, including hydroxyfluta-
mide- and bicalutamide-resistant AR variants T878A
and W742L/C, respectively. Other substitutions, includ-
ing L702H [10], V716M [50], V731M [51], T878S [11],
and H875Y [9], have been associated with receptor
promiscuity – that is, an increased AR sensitivity to
other steroids (progesterone, hydrocortisone, estradiol,
and so on) or to AR antagonists. We have also recently
reported four additional CRPC-associated variants,
S889G, D880E, L882I, and E894K located on exon 8 of
the AR gene [25].
In the current work, we employed a modified
mutation-identification pipeline that allowed us to estab-
lish a detailed cfDNA-based mutation status of all 62
CRPC patients reported in [25], thus including 15 pa-
tients that were previously excluded from the analysis
due to low DNA yield in their blood samples. The appli-
cation of an improved sequence analysis approach
allowed for the identification of four additional muta-
tions in the AR (H875Q D891H, E898G, and T919S).
We have also identified cases where two mutations
occur on the same haplotype: T878A/D891H, T878A/
S889G, F877L/T878A, H875Y/T878A, and H875Q/
T919S. We hypothesized that understanding the poten-
tial clinical significance of these mutations would require
in vitro functionalization to determine whether and how
the mutations modulate the activity of the AR.
The measured responses of 24 single and double AR
mutants to four AR antagonists, hydroxyflutamide,
bicalutamide, enzalutamide, and ARN509, revealed that
all these drugs can behave as AR agonists in the con-
text of certain mutations (Table 3). In particular, the
first generation antagonist hydroxyflutamide demon-
strated an activating behavior towards the vast majority
of the AR variants (with a notable exception of F877L),
ranging from weak to strong agonist for mutations
T878A/S, H875Y, F877L/T878A, T878A/D891H, and
T878A/S889G.
Resistance to bicalutamide was also observed for the
majority of the AR mutants, with the notable examples
of W742L/C, T878A/S, S889G, D891H, and M896V/T
mutations conferring strong bicalutamide activating phe-
notypes (Additional file 5: Figure S3). A partial agonist
Table 3 The response of CRPC-associated AR mutations to anti-
androgen treatments
AR mutants Agonist response to treatment
Hydroxyflutamide Bicalutamide Enzalutamide ARN509
L702H Partial Partial No No
V716M Partial Partial No No
V731M Partial Partial No No
W742L Partial Yes No No
W742C Partial Yes No No
H875Y Yes Partial Partial Partial
H875Q Partial Partial No No
F877L Partial No Partial partial
T878A Partial Yes Partial partial
T878S Partial Yes Partial partial
D880E Partial Partial No No
L882I Partial Partial No No
S889G Yes Yes No No
D891H Yes Yes No No
E894K Partial Partial No No
M896V Partial Yes No No
M896T Partial Yes No No
E898G Partial No No No
T919S Partial Partial No No
H875Q/T919S Partial Partial No No
T878A/S889G Yes Yes Partial Partial
T878A/D891H Yes Yes Partial No
F877L/ T878A No Yes Yes Yes
H875Y/T878A Yes Yes Partial Partial
Results presented in Additional file 4: Table S2 are summarized here. We
considered as partial agonist a drug that inhibited a mutant at low
concentrations and stimulated its activity at high concentrations
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response to bicalutamide was observed for the majority
of the studied mutants, especially when bicalutamide is
present at high concentrations. In particular, when
bicalutamide is administered above 16 μM, a profound
activation was detected for single mutations V716M,
V731M, H875Y, and for the mutation combinations
T878A/D891H and T878A/S889G. Knowing that the
steady state concentration of bicalutamide in the serum
of prostate cancer patients is 8.9 μg/mL or approxi-
mately 20 μM [52], we were surprised to find that in
our assay this drug activated the wild-type AR in the
same concentrations range (approximately 16 μM)
(Additional file 4: Table S2).
In addition to the documented case of enzalutamide-
resistant mutation F877L, we identified that the combin-
ation F877L/T878A behaved as full agonist and did not
show any inhibition in presence of enzalutamide. At
higher doses of enzalutamide, we observed a stimulation
of such mutants as T878A, H875Y, T878A/D891H, and
T878A/S889G.
Fig. 4 AR mutants associated with enzalutamide resistance in CRPC patients. a Molecular dynamics (MD) model of AR LBD (cartoon representation, in
gray) in complex with enzalutamide (ball-and-stick representation, in blue). The residues presented as gray sticks are found to be mutated in patients
progressing on enzalutamide treatment. b The F877L mutant showed an agonist response to enzalutamide in an in vitro cell-based assay
but was inhibited by the first generation anti-androgens hydroxyflutamide and bicalutamide. Each concentration was assayed in quadruplicate
n = 4, with a biological replicate of n = 3. Results were averaged and normalized by expressing them as a percentage of WT AR activity ± SEM
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The functionalization of these 24 CRPC-associated AR
mutants revealed that ARN509 generally exhibits dose-
response profiles similar to those of enzalutamide, in-
cluding agonist stimulation of mutants F877L, H875Y,
and T878A.
These experiments indicate that any of the 24 AR mu-
tants could drive resistance to at least one of the investi-
gated drugs. These observations point to a complex and
dynamic repertoire of AR mutations, driving therapeutic
resistance in CRPC. This is underscored by the observa-
tion that the AR LBD haplotypes and haplotype ratios in
cfDNA of individual CRPC patients can rapidly change
in response to treatment regimens.
An interesting example is a patient VC-012 (Fig. 2).
This individual underwent bicalutamide treatment
that resulted in the development of CRPC. At this
time-point, it was established that the patient’s AR
harbored mutations M896V and S889G in the ratio of
47 % to 53 %, respectively. In our assay both of these
mutations demonstrated profound resistance to bica-
lutamide (Fig. 2) and likely underlie the patient’s pro-
gression on bicalutamide. Importantly, both of these
mutations were sensitive to enzalutamide and could
be fully inhibited in vitro by 5 μM of the drug. Not-
ably, patient VC-012 was switched to enzalutamide
and after approximately 4 months of treatment, his
cfDNA was collected and sequenced. At this time-point,
the percentage of M896V and S889G had decreased to
4.7 % and 15.6 %, respectively. Remarkably, cfDNA se-
quencing revealed four new AR LBD mutations that
emerged in response to enzalutamide administration.
These new mutations included T878A (45.5 %), H875Y
(7.4 %), and two double mutants F877L/T878A (21.4 %)
and T878A/S889G (5.3 %). All four AR mutants demon-
strated varying degrees of activation by enzalutamide in
our assay (Fig. 2, Additional file 4: Table S2).
Structural basis for agonistic conversion of bicalutamide
and enzalutamide
The distinction between the agonistic and antagonistic ac-
tions of an AR ligand is conventionally attributed to the
induced motion of helix 12 – one of the receptor’s folds
forming the ABS cavity of the AR LBD. In a simplified
view, AR inhibitors are believed to push helix 12 outward,
preventing the formation of a ligand-locked, functional
(agonist) configuration of the protein [53, 54]. Using
methods of in silico modeling, we have investigated the
possible structural basis for the agonist conversion of bica-
lutamide toward M896V and S889G mutants (Additional
file 5: Figure S3), as well as the agonist interactions of
Fig. 5 Characterization of the in-house developed AR inhibitor VPC-13566. a Dose-response curve illustrating the inhibiting effect of the
VPC-13566 and enzalutamide on the AR transcriptional activity in PC3 cells transfected with wild-type AR plasmid. Data points represent the
mean of three independent experiments performed in four replicates each. Error bars represent the standard error of the mean ± SEM for n = 12 values.
b The specific binding to the BF3 site was confirmed by BAG1L peptide (1-20) displacement using a TR-FRET assay. c The effect of VPC-13566 on PC3
cell viability. % cell viability is plotted in dose dependent manner. Data points represent the mean ± SEM of two independent experiments performed
in quadruplicate
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T878A, H875Y, F877L/T878A, and T878A/S889G vari-
ants with enzalutamide (Fig. 4).
Our analysis of the distribution of the 15 mutated resi-
dues on the AR 3D structure demonstrated that they are
mainly clustered around the AR steroid binding site and
adjacent to helix 12 (Fig. 1). Previous structural studies
into AR mutants have associated the T878A mutation
with an increase in the size of the LBD cavity, the conse-
quence of replacing a threonine residue with a more
compact alanine residue. This size increase was attrib-
uted to the ability of the mutated AR to bind hydroxy-
flutamide in an agonist-like conformation [14]. Similarly,
the F877L mutation was shown to increase the size of
the AR ABS, thus enabling the receptor to accommodate
the enzalutamide moiety [20].
Residue M896 belongs to the above-mentioned helix
12 of the AR, and is in close contact with the sulfonyl
oxygen O15 of the bicalutamide molecule (1 Å), which
makes the agonist conformation improbable with the
WT-LBD (Additional file 3: Figure S2). The introduc-
tion of a less bulky non-polar valine residue into the
896-position should significantly increase the surface
area of the ABS pocket, therefore allowing bicaluta-
mide to bind in the closed agonist-like configuration.
In a similar way, one could consider the effect of
H875Y substitution: some preliminary modeling results
showed that the hydroxyl group of the Y875 side chain
can directly interact with -C(O)NHCH3 to further ac-
commodate the ligand into the agonist configuration of
the LBD.
The resistant character of the S889G substitution
could be attributed to the increased mobility of helix 12
in the AR. In fact, the S889 residue is positioned right at
the hinge of the helix 12, and introduction of the most
flexible amino acid – glycine – into that position should
significantly increase the mobility of the hinge, thus fa-
cilitating the motion of helix 12 toward the inbound lig-
and (Additional file 5: Figure S3).
We speculate that the double mutants F877L/T878A
and T878A/S889G combine the agonist effects of the
constituent single mutations. The intriguing possibility
of synergism arising from the LBD compound mutations
remains to be investigated.
Targeting new sites on the AR could overcome the
mutation-dependent drug resistance
The use of AR inhibitors that target the AR beyond its
conventional and mutation-prone ABS could provide an
effective strategy for addressing the problem of resist-
ance, either alone or in combination with ABS-targeted
agents such as enzalutamide. VPC-13566 has effectively
inhibited all AR variants, including those that confer re-
sistance to enzalutamide and to emerging drug candi-
dates such as ARN509 (Table 2 and Additional file 4:
Table S2). Thus, VPC-13566 could represent a viable
treatment option for CRPC patients. Moreover, our AR
BF3 inhibitor VPC-13566 exhibits a novel, distinctive
mode of action against the AR, and therefore, could be
considered for combinatorial therapy with conventional
AR antagonists with a view to reducing toxicity and un-
favorable side effects as well as delaying resistance of
conventional single agent therapy.
Conclusions
Genomic analysis of cfDNA is a minimally invasive
method for interrogating mechanisms of therapeutic re-
sistance in CRPC patients. In the present study, we dem-
onstrate that cfDNA sequencing can identify mutations
causally linked to resistance to therapies targeting the
AR in CRPC. In vitro functionalization revealed that all
24 investigated AR mutations exhibited resistance to at
least one of four AR inhibitors used in clinical practice.
Moreover, some of the newly identified double AR mu-
tants exhibited enhanced activation in presence of enza-
lutamide and ARN509 and/or demonstrated elevated
sensitivity to stimulation by DHT or others steroids.
These results underscore the importance of developing
therapeutics that target the AR at sites outside the ABS.
Thus, it is significant that the AR inhibitor VPC-13566,
targeting the AR BF3 pocket, can effectively block the
activity of all 24 AR mutants identified in CRPC patients.
It will now be important to determine if co-targeting the
AR with VPC-13566 and, for example, enzalutamide, can
delay/overcome the resistance. Finally, the results of this
study suggest that precision oncology for the improved
management of CRPC patients may be a feasible option to
improve patient care.
Methods
Patient cohort and sequencing of exon 8 of the AR gene
The cohort of 62 patients with metastatic CRPC re-
cruited at the British Columbia Cancer Agency (BCCA) -
Vancouver Prostate Centre (VPC, Vancouver, BC, Canada)
between August 2013 and March 2014 was described
previously [25]. In total, 19/62 (30 %) of patients were
switched onto enzalutamide after collection of cfDNA.
Clinico-pathological characteristics including prior and
subsequent therapies were recorded for each patient.
Blood collection, DNA isolation, and quantification were
performed as described previously [25].
For this paper we have sequenced blood samples from
15 patients that were reported as not sequenced in the
previous manuscript due to either low DNA yield (less
than 30 ng as determined by Qubit 2.0 measurement
using Qubit dsDNA HS Assay Kit) or repeatedly failed
to produce useable sequencing data (VC-024, VC-028
and VC-044). DNA was amplified with the Sigma
WGA2 kit (Cat No WGA2-10rxn or WGA2-50rxn) as
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per manufacturer’s instructions. The amplified material
was sequenced with the Roche 454 GS FLX+ system,
software version 2.9 as described in [25]. The amplicons
from three WGA2 samples with detected mutations
were also sequenced using an Illumina MiSeq sequencer;
in all cases the results were concordant.
Mutation calling
The biggest challenge in analysis of WGA2 amplified
DNA is the significantly higher noise levels introduced
by the genomic amplification. Therefore, we modified
our pipeline to assure tighter control and more precise
filtering of low-quality sequencing data. Raw sequence
reads were mapped to the human genome (hg19) using
BWA and visualized using the Integrative Genomics
Viewer (IGV) [55]. All possible non-reference bases
with greater than 25 Phred score at all amplicon loca-
tions were quantified using bam-readcount v. 0.7.4
(https://github.com/genome/bam-readcount) that allows
for direct filtering of reads at each base position based on
both sequence phred quality score (only bases with phred
score >25 were scored) and mapping score (only bases
with mapping score of >18 were scored). The raw base
counts for each qualified base were converted to percent-
age relative to sequence coverage at corresponding pos-
ition. We defined mutation candidates as non-reference
bases with percentage value greater than 4 standard devia-
tions distant to the mean and exceeding 0.1 % and 1 %
level in non-amplified samples and amplified samples, re-
spectively, due to increased background of base substitu-
tions in WGA2 data. All calls detected in more than 75 %
of sequenced samples were discarded as artifacts. We per-
formed manual curation of all detected calls, in some
cases adding calls that were present in other sequenced
samples from the same patient, provided that they could
be unambiguously identified as outliers on scatter plots of
matching samples. Finally, we performed haplotype fre-
quency estimation through manual curation of aligned
reads in IGV. Reads with >7 mismatches with the refer-
ence sequence were considered uninformative for samples
with multiple mutation calls.
Constructs
Full-length human AR (WT-AR) was encoded on a
pcDNA3.1 expression plasmid (Life technologies). The
LBD point mutations (single and multiple) were gener-
ated using the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technologies) as per manufacturer’s instruc-
tions using WT-AR as the template. The mutagenic
oligonucleotide primers were designed individually with
the desired mutation in the middle of the primer with
approximately 10 to 15 bases of correct sequence on
both sides.
Steroid activation assay
PC3 cells lacking the AR and authenticated by IDEXX La-
boratories (Maine, USA) were maintained in RPMI 1640
media (Life Technologies) and 5 % FBS (Hyclone Thermo
Fisher Scientific) at 37 °C and 5 % CO2. Cultures were
routinely monitored for mycoplasma contamination. For
the steroid activation assay, cells were seeded in 96-well
plates (5,000 cells/well) in RPMI 1640 medium with 5 %
charcoal-stripped serum (CSS) (Hyclone). After 24 h, cells
were co-transfected with 25 ng of wild-type or mutated
AR and 25 ng of the reporter plasmid pARR3-tk-luciferase
using TransIT20/20 transfection reagent (3 μL/μg of
DNA) (Mirus Bio LLC, Madison, WI, USA) in Optimem
serum-free media (Life Technologies) for 48 h according
to manufacturer’s suggested protocol. Cells were stimu-
lated with increasing concentrations of DHT, estradiol,
progesterone, or hydrocortisone in 100 % ethanol (0 to
500 nM). Control cells were treated with 100 % ethanol
alone. At 24 h after treatment, the medium was aspirated
off and the cells were lysed by adding 60 μL of 1× pas-
sive lysis buffer (Promega) followed by shaking at room
temperature for 15 min and two freeze/thaw cycles at
-80 °C . Twenty microliters of lysate from each well
were transferred onto a 96-well white flat bottom plate
(Corning) and the luminescence signal was measured
after adding 50 μL of luciferase assay reagent (Promega).
The chemical oxidation of luciferin into oxyluciferin by
the luciferase is accompanied by light production that can
be quantified as luminescence by a TECAN M200Pro in-
strument. Each concentration was assayed in quadrupli-
cate n = 4, with a biological replicate of n = 3. For each
steroid, results were averaged and normalized by express-
ing them as a percentage of WTAR activity.
AR inhibition assay
PC3 cells were seeded and transfected as described above.
At 48 h after transfection, medium was aspirated and re-
placed with medium containing 0.1 nM R1881 and either
0.1 % DMSO (control) or serial dilutions of increasing
concentrations of AR inhibitors ranging from 0 μM to
50 μM (hydroxyflutamide, bicalutamide, ARN509, enzalu-
tamide, and VPC-13566). A non-stimulated/no R1881
control was used. After 24 h, cells were lysed and AR-
dependent luciferase activity was quantified. Each con-
centration was assayed in quadruplicate n = 4, with a
biological replicate of n = 3. Results were averaged and
normalized by expressing them as a percentage of WT
AR activity.
Western blotting
Twenty microliters of each of the four replicates of
DMSO/control-treated lysate from the luciferase assay
were pooled with 20 uL of 5X sample buffer, boiled for
5 min, and 20 uL of the mixture was loaded on a 10 %
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SDS-PAGE gel and electrophoresed at 120 V for
90 min. Proteins were transferred to PVDF membrane
(Millipore) at 100 V for 1.5 h at 4 °C, blocked for 1 h at
room temperature with 5 % non-fat skim milk in TBS,
followed by incubation with 1/1,000 dilution of AR N20
antibody (sc-816, Santa Cruz Biotechnologies) over-
night at 4 °C. Membranes were incubated with 1/5,000
dilution of goat anti-rabbit IgG HRP (sc-2030, Santa
Cruz Biotechnologies) for 1 h at room temperature,
washed five times with TBS 0.1 % Tween 20 (Sigma),
and bands visualized using Super Signal West Femto
(Thermo Scientific) and a digital imager (Syngene G Box).
Lanthascreen TR-FRET displacement assay
The displacement of a fluorescein isothiocyanate (FITC)
labeled BAG1L peptide (FITC-MAQRGGARRPRGDR
ERLGSR) from the BF3 pocket of the LBD by the com-
pounds VPC13566 and VPC14449 was assessed using a
Time-Resolved Fluorescence Energy Transfer (TR-FRET).
Compounds were tested in the range of 0.41 to 100 μM in
a final concentration of 1.5 % DMSO. The protein AR-
LBD, the FITC-BAG1L peptide, and the LanthaScreen®
Elite Terbium-labeled anti-His-tag antibody (Life Tech-
nologies, PV5863) were used at final concentrations of
100 nM, 500 nM, and 5 nM, respectively. Briefly, the
(His)6-tagged AR-LBD was prepared at 4X final concen-
tration in the buffer (150 mM Li2SO4, 50 mM HEPES
pH7.5, 10 % Glycerol, 20 μM of DHT and 0.5 mM
tris(2-carboxyethyl)phosphine) in the presence of 4X
Tb-anti-His-antibody (Mix A). Mix B contained 4X
FITC-BAG1L peptide in 2 % DMSO. A three-fold serial
dilution of the compounds was prepared at 100X final
concentration in DMSO. The compounds were then di-
luted 50-fold in buffer to get a 2X final concentration
and 2 % DMSO (Mix C). In a black flat bottom 384-
well plate 5 μL of Mix A, 5 μL of Mix B, and 10 μL of
Mix C were added.
The plate was incubated at room temperature for 2 h
and FRET was analyzed on Synergy-4 multi-plate reader
with the following settings: excitation, 340 nm; emission,
495 nm and 520 nm. The emission ratio (520:495) was
analyzed, normalized to the buffer, and plotted.
Cell viability assay
PC3 cells were plated at 5,000 cells per well in RPMI
1640 containing 5 % CSS in a 96-well plate and treated,
after 72 h, with 0.1 nM R1881 and VPC-13566 (0-50 μM).
After treatment for 24 h, cell density was measured using
the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay according
to the manufacturer’s protocol (CellTiter 961 Aqueous
One Solution Reagent, Promega). The percentage of cell
survival was normalized to the cell density of control wells
treated by vehicle and 0.1 nM R1881.
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Additional file 2: Figure S1. Western blot showing expression level of
the CRPC-associated AR mutants in PC3 transfected cells. (TIF 351 kb)
Additional file 3: Figure S2. Activation of wild-type AR by dihydrotes-
tosterone (DHT), progesterone, estradiol, and hydrocortisone. The graphs
represent the average ± SEM of three independent experiments with four
replicates each. (TIF 252 kb)
Additional file 4: Table S2. The response of the CRPC-associated
mutants to increasing concentrations of anti-androgens. Abiraterone,
bicalutamide, hydroxyflutamide, enzalutamide, ARN509, and an in-house
developed AR inhibitor VPC-13566 were tested against the 24 CRPC-
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normalized by expressing them as a percentage of WT AR activity ± SEM.
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Additional file 5: Figure S3. AR mutants associated with bicalutamide
resistance in CRPC patients. (a) The AR LBD (cartoon representation, in
gray) in complex with bicalutamide (ball-and-stick representation, in
blue). The residues presented as gray sticks presented an agonist effect in
the presence of bicalutamide in luciferase reporter transcription assay.
The B ring of bicalutamide occupies the position that would normally be
filled by the indole ring of tryptophan in the non-mutated W741 position
(shown in transparent gray) in the LBD. (B) AR mutants showing agonist
responses to bicalutamide by in vitro functional characterization. Each
concentration was assayed in quadruplicate n = 4, with a biological replicate
of n = 3. Results were averaged and normalized by expressing them as a
percentage of WT AR activity ± SEM. (TIF 1129 kb)
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